Formulation and Evaluation of Dapagliflozin-Loaded Nanoemulsion using a Box–Behnken design for Antidiabetic Delivery
Dapagliflozin (DG), is Sodium-Glucose Cotransporter 2 inhibitor approved for the treatment of type 2 diabetes that Lowers blood glucose levels by helping the body expel excess sugar through urine. The drug faces clinical limitations like not recommended for patients with polycystic kidney disease and may cause hypoglyc...